oxybutynin has been researched along with Dermatitis Medicamentosa in 7 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It compares the bioavailability of these two study drugs from a TDDS with conventional immediate release oral tablets in healthy volunteers." | 2.75 | Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ( Aggarwal, A; Agrawal, SS, 2010) |
| "To identify and characterize cases of chemical leukoderma, an underrecognized adverse event, associated with the methylphenidate transdermal system (MTS) reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS)." | 1.46 | Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System. ( Brinker, A; Cheng, C; Diak, IL; La Grenade, L; Levin, RL, 2017) |
| "Solitary fixed drug eruptions involving the lips and mouth are known to occur but are rarely seen in oral medicine clinical practice." | 1.35 | Fixed drug eruption to oxybutynin. ( Pemberton, MN; Sloan, P; Yar, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Pemberton, MN | 1 |
| Yar, R | 1 |
| Sloan, P | 1 |
| Asano, A | 1 |
| Nakai, K | 1 |
| Tsuruta, D | 1 |
| Golüke, NM | 1 |
| van Strien, AM | 1 |
| Dautzenberg, PJ | 1 |
| Jessurun, N | 1 |
| Keijsers, CJ | 1 |
| Alva, G | 1 |
| Cummings, JL | 1 |
| Galvin, JE | 1 |
| Meng, X | 1 |
| Velting, DM | 1 |
| Cheng, C | 1 |
| La Grenade, L | 1 |
| Diak, IL | 1 |
| Brinker, A | 1 |
| Levin, RL | 1 |
| Agrawal, SS | 1 |
| Aggarwal, A | 1 |
| Segers, K | 1 |
| Cytryn, E | 1 |
| Surquin, M | 1 |
1 trial available for oxybutynin and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antihypertensive Agents; Area Under Curve; B | 2010 |
6 other studies available for oxybutynin and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Fixed drug eruption to oxybutynin.
Topics: Cholinergic Agents; Drug Eruptions; Humans; Lip Diseases; Male; Mandelic Acids; Middle Aged; Oral Ul | 2008 |
Lichenoid drug eruption associated with bisoprolol transdermal patches.
Topics: Administration, Cutaneous; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Delayed-Action Prepar | 2022 |
Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report.
Topics: Administration, Oral; Aged; Cholinesterase Inhibitors; Drug Eruptions; Galantamine; Humans; Male; Ph | 2014 |
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Eruptions | 2015 |
Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Central Nervous System Stimulants; Child | 2017 |
Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Belgium; Cholinesterase Inhibitors; Delirium; Drug Erupt | 2012 |